Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR)

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 607-613

  Dore, Gregory J ^a   Cooper, David A ^a   Barrett, Catherine ^b   Goh, Li Ean ^b   Thakrar, Bharat ^b   Atkins, Mark ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LOVIRIDE; PLACEBO; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACETAMIDES; ACETOPHENONES; ADULT; AGED; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PLACEBOS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0032850214     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314942     Document Type: Article

References (28)

1. 1. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus typ 1 on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
2. 2. Gilson RJC, Hawkins AE, Beecham MR. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606.
3. 3. Lazizi Y, Grangeot-Keros L, Delfraissy JF, et al. Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1 [letter]. J Infect Dis 1988;158:666-7.
4. 4. Vento S, Di Perri G, Luzzati R, et al. Clinical reactivation of hepatitis B in anti HBs-positive patients with AIDS [letter]. Lancet 1989;1:332-3.
5. 5. Waite J, Gilson RJC, Weller TVD, et al. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 1988; 2:443-8.
6. 6. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348: 283-91.
7. 7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
8. 8. Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992;36:202-5.
9. 9. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-9.
10. 10. Staszewski S, Hill AM, Bartlett J, et al. Reductions in HIV-1 disease progression for ZDV/3TC relative to control treatments; a meta-analysis of controlled trials, AIDS 1997;11:477-83.
11. 11. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349: 1413-21.
12. 12. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
13. 13. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
14. 14. Lai CL. Ching CK, Tung AKM, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-4.
15. 15. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
16. 16. Benhamou Y, Dohin E, Lunei-Fabiani F, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients [letter]. Lancet 1995;345:396-7.
17. 17. Schnittman SM, Pierce PF. Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient with human immunodeficiency virus type 1 [letter]. Clin Infect Dis 1996;23:638-9.
18. 18. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17): 1-19.
19. 19. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;17:103-6.
20. 20. Honkoop P, de Man RA, heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine [letter]. Lancet 1995;346:1156-7.
21. 21. Zylberberg H, Jiang J, Pialoux G, et al. Alpha-interferon for chronic hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996;20:968-71.
22. 22. Wong DKH, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-71.
23. 23. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995-6.
24. 24. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-2.
25. 25. Schinazi RF, Lloyd RM, Nguyen MH, et al. Characterization of human immodeficiency virus resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37:875-81.
26. 26. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
27. 27. Dore GJ, Brown T, Tarantola D, Kaldor JM, HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS 1998; 12(Suppl B): S1-10.
28. 28. Gust ID. Epidemiology of hepatitis B infection in the western Pacific and Southeast Asia. Gut 1996;38(Suppl 2):S18-23.